Skip to main content

Table 2 Patient and treatment characteristics

From: Incorporating 18FDG-PET-defined pelvic active bone marrow in the automatic treatment planning process of anal cancer patients undergoing chemo-radiation

Variable N° (%)
Age
 Mean 65
 Rage 50–78
Sex
 Female 5 (50%)
 Male 5 (50%)
T stage
 T2 5 (50%)
 T3 5 (50%)
N stage
 N0–1 2 (20%)
 N2 6 (60%)
 N3 2 (20%)
Global stage
 II 2 (20%)
 IIIB 8 (80%)
PTV dose-tumor (Gy)
 54 Gy 10 (100%)
PTV dose-positive nodes (Gy)
 54 Gy 2 (20%)
 50.4 Gy 5 (50%)
PTV dose-elective volumes (Gy)
 45 Gy 10 (10%)
  1. Legend: T tumor, N nodal, number, PTV planned target volume